Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CLRB | PRESS-RELEASE | neutral | 1/10 | Cellectar Biosciences, Inc. announced it will report its Q1 results on May 14, 2026. | May 11, 2026 |
| HRTX | PRESS-RELEASE | bearish | 6/10 | Heron Therapeutics reported Q1 2026 net revenue of $34.7M, down 10.8% YoY, and a GAAP net loss of $8.1M ($-0.04/share) v | May 11, 2026 |
| CMND | PRESS-RELEASE | neutral | 2/10 | Clearmind Medicine announced a live webinar on June 10, 2026, to discuss early clinical data from its Phase I/IIa trial | May 11, 2026 |
| ATHE | PRESS-RELEASE | bullish | 7/10 | Alterity Therapeutics announced a peer-reviewed publication in NeuroImage demonstrating that QSM MRI can detect disease- | May 11, 2026 |
| APGE | PRESS-RELEASE | bullish | 7/10 | Apogee Therapeutics reported Q1 2026 EPS of -$1.03, a 9% beat vs consensus of -$1.13, with no revenue. The company highl | May 11, 2026 |
| LXEO | PRESS-RELEASE | bullish | 6/10 | Lexeo Therapeutics reported Q1 2026 net loss of $0.25 per share, beating consensus estimates of -$0.30 by 16.7%, with re | May 11, 2026 |
| GANX | PRESS-RELEASE | neutral | 4/10 | Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat is marginal for a pr | May 11, 2026 |
| MBX | PRESS-RELEASE | mixed | 6/10 | MBX Biosciences reported preliminary Phase 1 data for MBX 4291 (GLP-1/GIP co-agonist prodrug) showing 7% mean weight los | May 11, 2026 |
| ERAS | PRESS-RELEASE | neutral | 4/10 | Erasca announced a clinical trial collaboration with Merck to evaluate its pan-RAS molecular glue ERAS-0015 in combinati | May 11, 2026 |
| LQDA | PRESS-RELEASE | bullish | 7/10 | Liquidia reported Q1 2026 revenue of $132.9M (driven by YUTREPIA sales of $129.9M) and net income of $52.9M ($0.52 dilut | May 11, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech announced that the FDA completed a routine cGMP surveillance inspection of its Reykjavik facility, issuing a Fo | May 11, 2026 |
| ALVO | PRESS-RELEASE | bullish | 6/10 | Alvotech announced FDA completed a cGMP surveillance inspection of its manufacturing facility, issuing a Form 483 with o | May 11, 2026 |
| MLTX | PRESS-RELEASE | bullish | 7/10 | MoonLake announced a successful final pre-BLA meeting with the FDA, aligning on submission plans and label strategy for | May 10, 2026 |
| ISPC | PRESS-RELEASE | bearish | 6/10 | iSpecimen priced a ~$2.5M private placement, issuing 488,281 shares at $5.12/share with pre-funded warrants, for working | May 8, 2026 |
| ARGX | PRESS-RELEASE | bullish | 7/10 | FDA approved label expansion for VYVGART and VYVGART Hytrulo to treat all serotypes of generalized myasthenia gravis (gM | May 8, 2026 |
| INKT | PRESS-RELEASE | neutral | 1/10 | MiNK Therapeutics announced it will report its Q1 2026 results on May 15, 2026. | May 8, 2026 |
| VTVT | PRESS-RELEASE | neutral | 2/10 | vTv Therapeutics granted 39,500 stock options to two non-executive employees as inducement awards. This is a routine com | May 8, 2026 |
| BFRI | PRESS-RELEASE | neutral | 1/10 | Biofrontera Inc. announced it will report its Q1 2026 results on May 14, 2026. | May 8, 2026 |
| CYTK | PRESS-RELEASE | bearish | 6/10 | Cytokinetics closed an underwritten public offering of 11.3 million shares at $71.00 per share, raising approximately $8 | May 8, 2026 |
| ALLR | PRESS-RELEASE | neutral | 2/10 | Allarity Therapeutics CEO Thomas Jensen will present at Precision Medicine Forum Europe 2026 on May 11, discussing steno | May 8, 2026 |
| CGON | PRESS-RELEASE | neutral | 5/10 | CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago, | May 8, 2026 |
| HUMA | PRESS-RELEASE | neutral | 1/10 | Humacyte, Inc announced it will report its Q1 2026 results on May 13, 2026. | May 8, 2026 |
| ALXO | PRESS-RELEASE | bearish | 6/10 | ALX Oncology reported Q1 2026 GAAP EPS of -$0.17, significantly missing the consensus estimate of -$0.16 (a -6.25% miss) | May 8, 2026 |
| ALMR | PRESS-RELEASE | bullish | 7/10 | Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consumable growth and 78% | May 8, 2026 |
| TRAW | PRESS-RELEASE | neutral | 4/10 | Traws Pharma announced plans to develop clinical candidates for hantavirus treatment following a recent outbreak linked | May 8, 2026 |
| PSTV | PRESS-RELEASE | bullish | 6/10 | Plus Therapeutics presented a plenary session at the 2026 AANS Annual Meeting highlighting Phase 1 ReSPECT-LM data for R | May 8, 2026 |
| HYPD | PRESS-RELEASE | bearish | 6/10 | Hyperion DeFi closed a public offering of 2,777,778 shares at $3.60 per share, raising approximately $10.0 million in gr | May 8, 2026 |
| BOLD | PRESS-RELEASE | bearish | 6/10 | Boundless Bio reported Q1 2026 net loss of $13.6M ($0.60/share), wider than the consensus estimate of $0.56 loss per sha | May 8, 2026 |
| TVRD | PRESS-RELEASE | neutral | 4/10 | Tvardi Therapeutics reported Q1 2026 EPS of -$0.73, missing consensus of -$0.72 by 1.4% (in-line), with no revenue. The | May 8, 2026 |
| ANIP | PRESS-RELEASE | bullish | 8/10 | ANI Pharmaceuticals reported Q1 2026 adjusted non-GAAP diluted EPS of $2.05, beating the $1.30 consensus by 57.7%, on re | May 8, 2026 |